- This topic has 0 replies, 1 voice, and was last updated 1 month, 2 weeks ago by .
-
Posts
-
Good Morning Fellow HRA Members!
The ALS Association has extended the deadline for our 2026 Hoffman ALS Clinical Trial Awards. Letters of intent are now due Tuesday, November 18, 2025, 1 p.m. US ET.
Overview
This program supports early- to mid-stage (phase 1 or 2a) biomarker-driven clinical trials of novel or repurposed therapeutics for ALS (either disease-modifying or symptomatic). Early trials testing imaging tracers are also in scope. Both industry and academic investigators are eligible to apply.Successful applications will:
- Include a clear and compelling biological rationale for the target biology and pathway.
- Include a robust preclinical data package providing the rationale for the proposed treatment/tracer moving to the clinical stage.
- Have an integrated biomarkers program that uses robust, reliable, replicable, and reproducible assays with clearly defined contexts of use.
- Propose outcomes that are aligned with the trial phase.
- Provide a clear plan, including “go/no-go” decision milestones, for moving the approach through the essential stages of clinical development.
- Describe what additional funding sources are in hand already or will be pursued to fund the entire trial (e.g., government, private/VC investors, industry partnerships, etc.).
For a list of previously funded projects, please visit our website.
Funding and Award Information
- Funding Amount: Up to $1,000,000 (inclusive of both direct and indirect costs)
- Grant Duration: 2 or 3 years
- Indirect Costs: Limited to 10% of total direct costs when PI salary is waived
Application Timeline
- Letter of Intent Due: November 18, 2025, 1 p.m. US ET
- Full Proposal Due (by invitation only): February 17, 2026, 1 p.m. US ET
- Anticipated Award Decision: May 2026
- Anticipated Earliest Start Date: July 1, 2026
We would appreciate any help in spreading the word to your networks! Click here for more information and submission guidelines. If you have any questions, please email [email protected].
Sincerely,
The ALS Association Research Team
- You must be logged in to reply to this topic.